Graft-versus-host disease affects 30–70% of allogeneic hematopoietic stem cell transplant recipients, making it the single most consequential complication of what is often a life-saving procedure. [1] In its acute, steroid-refractory form, GvHD carries a mortality rate approaching 80% — and until the arrival of mesenchymal stem cell therapy, clinicians had few options beyond escalating immunosuppression that frequently proved futile. MSC therapy is the only cell-based treatment to earn regulatory approval for steroid-refractory GvHD, a distinction grounded in over 15 years of clinical investigation.

Where conventional treatment falls short. First-line therapy for acute GvHD is high-dose corticosteroids, typically methylprednisolone at 1–2 mg/kg/day. When patients fail to respond within 3–5 days — or progress after an initial response — they are classified as steroid-refractory. Second-line options (anti-thymocyte globulin, extracorporeal photopheresis, pentostatin, etanercept, ruxolitinib) offer variable response rates of 20–50% and carry substantial toxicity. The unmet need in steroid-refractory disease has been the primary driver of MSC research in GvHD. [2]

The deeper problem is donor T-cell attack on host tissue. In allogeneic transplantation, donor-derived T lymphocytes recognize host tissues as foreign and mount a destructive immune assault targeting the skin, gastrointestinal tract, and liver — the three organ systems most commonly affected in GvHD. The pathophysiology involves conditioning-regimen tissue damage releasing danger signals, activation of donor T cells by host antigen-presenting cells, and an escalating cascade of pro-inflammatory cytokines (TNF-α, IL-1, IL-6, IFN-γ) that amplifies tissue destruction. [3] Standard immunosuppression blunts this cascade broadly; MSCs target it with remarkable precision.

MSC therapy targets the root cause. Rather than globally suppressing the immune system as corticosteroids do, mesenchymal stem cells home to sites of inflammation and deliver site-specific immunomodulation — suppressing the alloreactive donor T cells that drive GvHD while paradoxically preserving the graft-versus-leukemia (GvL) effect critical for preventing cancer relapse. This selectivity — quelling GvHD without compromising GvL — represents the therapeutic ideal that has driven two decades of clinical investigation. [4]

Understanding Graft-versus-Host Disease: Beyond the Acronym

Graft-versus-host disease occurs when immunocompetent donor T cells transplanted with the stem cell graft recognize recipient tissues as foreign and initiate a destructive immune response. It is classified as acute GvHD (aGvHD) — occurring within 100 days of transplant, typically affecting skin (maculopapular rash), gastrointestinal tract (diarrhea, nausea, anorexia), and liver (cholestatic jaundice) — and chronic GvHD (cGvHD), which manifests later and can resemble autoimmune conditions including scleroderma, Sjögren's-like sicca syndrome, and bronchiolitis obliterans.

The global incidence is substantial: aGvHD develops in 30–50% of HLA-matched sibling transplants and 50–70% of unrelated donor transplants, despite standard prophylaxis with calcineurin inhibitors and methotrexate. [5] Approximately 40–50% of patients with grade II–IV aGvHD become steroid-refractory — the population for whom MSC therapy is specifically indicated and approved in several jurisdictions.

The immunological cascade. GvHD pathophysiology proceeds through three phases: (1) conditioning-regimen damage to host tissues releases inflammatory cytokines and exposes alloantigens; (2) donor T cells recognize these alloantigens, proliferate, and differentiate into effector cells secreting IL-2, IFN-γ, and TNF-α; (3) these effector cells and cytokines mediate end-organ damage. MSCs intervene at phase 2 — the T-cell activation and proliferation stage — and at the cytokine amplification loop of phase 3.

Key point: GvHD is not simply "rejection" — it is the opposite problem. The graft (donor cells) rejects the host (patient). This immunological inversion means therapies that suppress the host immune system are ineffective; the target must be the donor's alloreactive T cells. MSC therapy is uniquely suited to this task because it suppresses donor T-cell activation without globally ablating immune function.

How MSC Therapy Works in GvHD: Four Mechanisms of Action

MSCs exert their therapeutic effect in GvHD through four interconnected mechanisms that collectively suppress the alloreactive donor T-cell response while preserving beneficial immune functions. These mechanisms are exceptionally well-characterized in the GvHD context — arguably more so than in any other disease indication — because GvHD was the first and most intensively studied MSC clinical application.

Direct suppression of alloreactive T cells. MSCs inhibit the proliferation of activated CD4+ and CD8+ donor T cells through both contact-dependent and soluble-factor mechanisms. Key mediators include indoleamine 2,3-dioxygenase (IDO), which depletes local tryptophan and generates kynurenine metabolites toxic to proliferating T cells; prostaglandin E2 (PGE2), which suppresses T-cell receptor signaling; and programmed death-ligand 1 (PD-L1), which delivers an inhibitory signal through the PD-1 receptor on activated T cells. [6] This suppression is not global — MSCs preferentially target alloreactive T cells while sparing resting memory T cells important for anti-infective immunity.

Induction of regulatory T cells (Tregs). MSCs shift the immune environment from a pro-inflammatory Th1/Th17 profile toward a tolerogenic Treg-dominant state. They do this by secreting TGF-β and HLA-G5, which promote the conversion of naïve CD4+ T cells into functional FoxP3+ regulatory T cells, and by modulating dendritic cell maturation such that antigen presentation favors tolerance rather than immunity. [7] Expanded Treg populations actively suppress the alloreactive T cells driving GvHD, creating a self-sustaining tolerogenic environment that persists beyond the lifespan of the infused MSCs themselves.

Cytokine storm attenuation. Acute GvHD is characterized by a "cytokine storm" — dangerously elevated levels of TNF-α, IL-1β, IL-6, and IFN-γ — that amplifies tissue damage in a positive-feedback loop. MSCs interrupt this loop by secreting soluble TNF-α receptor 1 (sTNFR1) and IL-1 receptor antagonist (IL-1RA), directly neutralizing the two most potent pro-inflammatory mediators in the GvHD cascade. They also upregulate IL-10 production from host macrophages, shifting the cytokine milieu from destructive to regulatory. [8]

Tissue repair and preservation of graft-versus-leukemia effect. Unlike corticosteroids and calcineurin inhibitors — which suppress all T-cell function indiscriminately — MSCs appear to maintain the graft-versus-leukemia (GvL) effect by preferentially suppressing alloreactive T cells directed against host tissues while sparing T cells that recognize leukemia-associated antigens. [9] Additionally, MSCs secrete angiogenic and anti-apoptotic factors (VEGF, HGF, KGF) that promote repair of conditioning-damaged gastrointestinal epithelium and hepatic tissue — directly addressing end-organ pathology rather than simply suppressing its cause.

Clinical insight: The four-mechanism model — direct T-cell suppression, Treg induction, cytokine storm attenuation, and tissue repair with GvL preservation — explains why MSC therapy has consistently outperformed single-mechanism second-line agents in GvHD. No other therapy addresses all four components of the disease simultaneously. The translational question is not whether MSCs work in GvHD — they clearly do — but how to optimize dose, timing, and cell source to maximize the consistently observed 50–70% overall response rates in steroid-refractory patients.

Clinical Evidence: From First-in-Human to Regulatory Approval

The clinical development of MSC therapy for GvHD represents one of the most methodical and well-documented translational trajectories in cell therapy — spanning a landmark case report, multiple phase 2 trials, and the first regulatory approvals of an allogeneic cell-based therapeutic for any indication.

Le Blanc et al. (2004) — The index case. The GvHD story began with a single patient: a 9-year-old boy with steroid-refractory grade IV acute GvHD involving the gut and liver after an unrelated donor transplant for acute lymphoblastic leukemia. The Karolinska Institute team infused haploidentical bone marrow-derived MSCs from the patient's mother. The result — rapid resolution of diarrhea, normalization of bilirubin, and survival to discharge — was published in Bone Marrow Transplantation and sparked worldwide interest. [10]

Le Blanc et al. (2008) — The landmark phase 2 study. In a multicenter European study published in The Lancet, 55 patients with steroid-refractory grade II–IV acute GvHD received allogeneic bone marrow-derived MSCs (median dose 1.4 × 10⁶ cells/kg). The complete response rate was 30 of 55 patients (55%), with responses observed across all grades and all affected organs. Critically, complete responders had significantly improved overall survival at 2 years (52% vs. 16% for non-responders). The safety profile was benign. [11] This study established the benchmark against which all subsequent GvHD MSC trials have been measured.

Kurtzberg et al. (2014) — Remestemcel-L in pediatric GvHD. A phase 2 trial of remestemcel-L (ex vivo cultured adult human MSCs, later branded as Prochymal and Ryoncil) enrolled 75 pediatric patients with steroid-refractory grade B–D acute GvHD. Day 28 overall response rate was 64%, with complete responses in 36% of patients. Responders had significantly higher day 100 survival (78% vs. 31%). [12]

Regulatory milestones. In 2012, Health Canada approved Prochymal (remestemcel-L) for the management of acute GvHD in children — the world's first regulatory approval of a manufactured allogeneic stem cell product. In 2015, Japan's PMDA approved Temcell HS (JCR Pharmaceuticals), the same remestemcel-L product manufactured under license, for acute GvHD in both adults and children under Japan's regenerative medicine framework. In 2024, the FDA approved Ryoncil (remestemcel-L) for steroid-refractory acute GvHD in pediatric patients 2 months of age and older — the first MSC therapy approved in the United States. [13]

Kebriaei et al. (2023) — Real-world registry data. Analysis of 241 patients from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry who received MSC therapy for GvHD reported a day 28 overall response rate of 60.4% with a day 100 survival of 62.2%. These real-world outcomes closely mirror the clinical trial data and provide external validation of efficacy outside the controlled trial setting. [14]

Limitations to acknowledge: Despite regulatory approvals, an important nuance warrants transparency. The phase 3 trial of remestemcel-L in pediatric GvHD (NCT00366145) did not meet its primary endpoint of durable complete response at day 28 (35% vs. 30% for placebo, p=0.42), mainly due to a higher-than-expected placebo response rate. Approval in Canada, Japan, and the US was based on the totality of phase 2 and real-world evidence plus a favorable benefit-risk profile in a condition with 80% mortality and no approved alternatives. MSC therapy for GvHD should be understood as a treatment with strong phase 2 evidence, real-world corroboration, and regulatory acknowledgment of unmet need — not as a therapy proven superior to placebo in a successful phase 3 trial.

What Patients and Families Might Expect: Timeline and Response Patterns

Based on published clinical protocols and real-world treatment data, the typical course of MSC therapy for steroid-refractory acute GvHD follows a well-characterized sequence. The following timeline reflects what clinical studies describe — it is not a guarantee of response, but a representative trajectory.

Day 0
MSC Infusion

Allogeneic bone marrow-derived or umbilical cord-derived MSCs are administered intravenously — typically at a dose of 2 × 10⁶ cells/kg per infusion, given twice weekly for 4 weeks. The infusion is well tolerated in the vast majority of patients; infusion-related reactions are rare and generally mild. No HLA matching is required between the MSC donor and the patient — MSCs are immunoprivileged and do not provoke alloreactivity.

Days 1–7
Early Signs of Response

In responders, the earliest clinical improvements typically manifest within the first week — reduced stool volume in gastrointestinal GvHD, improvement in skin rash erythema and extent, and stabilization of liver function tests. The median time to initial response across studies is 4–7 days. A lack of any clinical improvement by day 14 strongly predicts non-response.

Days 7–28
Response Assessment Window

Day 28 is the primary efficacy endpoint in most studies. Complete response is defined as resolution of all GvHD manifestations in all affected organs; partial response is ≥50% improvement in organ staging without worsening in any organ. Overall response rates (CR + PR) at day 28 range from 55–70% across published studies. Steroid tapering typically begins once a response is established.

Days 28–100
Durability and Survival

Among day 28 responders, approximately 70% maintain their response through day 100. One-year overall survival for complete responders is 50–70% — substantially better than the 10–15% survival for steroid-refractory patients treated with conventional second-line agents. The survival benefit is driven primarily by reduced GvHD-related mortality rather than by effects on infection or relapse.

The VELAR Approach: Cell Quality for an Immunologically Complex Indication

GvHD is an acute, life-threatening condition with narrow therapeutic windows — cell quality, potency, and timely availability are not negotiable variables. The VELAR laboratory operates with the recognition that patients considering MSC therapy for GvHD need reproducible cell products manufactured to standards consistent with those used in the published clinical trials.

Allogeneic Wharton's Jelly-derived MSCs. VELAR uses mesenchymal stem cells sourced from Wharton's jelly of donated umbilical cord tissue — biologically young, highly proliferative cells with robust immunomodulatory potency. Allogeneic MSCs are essential for GvHD because autologous MSCs from the transplant recipient are often functionally compromised by prior chemotherapy and the underlying malignancy.

ISCT identity criteria and potency testing. Every cell batch is verified to meet International Society for Cell & Gene Therapy (ISCT) criteria: plastic adherence in culture, ≥95% expression of CD73/CD90/CD105 surface markers, ≤2% hematopoietic lineage markers (CD34/CD45/CD11b/CD19/HLA-DR), and trilineage (osteogenic, adipogenic, chondrogenic) differentiation capacity. [15] For GvHD specifically, in vitro T-cell suppression assays — measuring the ability of each batch to inhibit anti-CD3/CD28-stimulated T-cell proliferation — confirm functional potency beyond identity criteria alone.

GMP-compliant processing. All manufacturing steps — from tissue procurement through cell isolation, culture expansion, cryopreservation, and final product release — are conducted under ISO 9001:2015 certified quality management, OECD GLP principles, and in a facility accredited by AAALAC International. Multi-pathogen screening including sterility, mycoplasma, and endotoxin testing is completed on every batch. The frozen product is shipped in validated cryogenic containers and thawed at the point of care immediately prior to intravenous administration.

Frequently Asked Questions

Is MSC therapy a cure for graft-versus-host disease?

MSC therapy is not positioned as a universal cure, but it is the only cell-based treatment with regulatory approval for steroid-refractory acute GvHD. In published studies, it achieves complete resolution of all GvHD manifestations in approximately 30–55% of steroid-refractory patients and partial improvement in an additional 20–30%. For a condition with 80% mortality in its steroid-refractory form, these response rates represent a clinically meaningful advance — but they are not universal, and not all patients respond.

Do MSCs interfere with the graft-versus-leukemia effect?

Preclinical and clinical evidence suggests that MSCs preserve the beneficial graft-versus-leukemia effect — the very reason the transplant was performed in the first place — even as they suppress the harmful alloreactive T cells driving GvHD. Relapse rates in published MSC-treated GvHD cohorts are not higher than expected for the underlying disease. This selectivity is perhaps the single most important advantage of MSCs over broad immunosuppressants.

How quickly can treatment be initiated?

Because allogeneic MSCs are an off-the-shelf product — manufactured, cryopreserved, and stored in advance — there is no donor identification, collection, or manufacturing delay. Once steroid-refractoriness is established (typically day 3–5 of corticosteroid therapy without response), MSCs can be infused within 24–48 hours of the clinical decision. Speed matters in acute GvHD, where clinical deterioration can be rapid.

What cell source is used for GvHD?

The landmark clinical studies used bone marrow-derived MSCs from healthy donors. Umbilical cord-derived MSCs (Wharton's jelly MSCs) have subsequently been shown to possess comparable — and in some assays superior — immunomodulatory potency, with the practical advantage of ready availability from donated birth tissue without the need for a bone marrow harvest from a living donor. VELAR uses Wharton's jelly-derived MSCs, consistent with the cell source used in several positive phase 2 GvHD studies from Chinese and Korean investigators.

Are there GvHD-specific risks?

The safety profile of allogeneic MSC infusion across all published GvHD studies is remarkably benign — no infusion-related fatalities, no ectopic tissue formation, no MSC-related malignancies, and no increase in infection rate. The most common adverse events are transient (mild fever, chills) and resolve within hours. The primary risk is treatment failure — non-response or partial response — which affects approximately 30–45% of patients and requires prompt transition to alternative second-line therapy.

What does treatment cost in Bangkok?

Costs vary based on cell dose, number of infusions, and whether the patient requires inpatient admission for unrelated transplant complications. GvHD treatment at VELAR is priced substantially below equivalent MSC therapy in North America or Europe. A candid discussion with the clinical team — including a personalized treatment plan and transparent cost breakdown — is provided during the initial consultation. Patients or families should not delay inquiry due to cost uncertainty; VELAR provides financial clarity before any treatment commitment.

Limitations and Honest Assessment

MSC therapy for graft-versus-host disease is the most evidence-rich indication in the entire MSC field — and it still has meaningful limitations that patients, families, and referring physicians must understand. The phase 3 trial in pediatric GvHD did not meet its primary endpoint due to a high placebo response rate, and regulatory approvals in Canada, Japan, and the US relied on phase 2 data plus real-world evidence rather than a positive phase 3 result. Approximately 30–45% of patients do not respond to MSC therapy at all, and among responders, not all responses are durable.

The optimal dose, schedule, and cell source remain under investigation. The relative efficacy of bone marrow-derived versus umbilical cord-derived MSCs has not been established in a head-to-head trial. Biomarkers predicting response — T-cell repertoire profiling, cytokine signatures, or HLA expression patterns — are being researched but are not yet validated for clinical use in patient selection.

Nevertheless, in the context of steroid-refractory grade II–IV acute GvHD — a condition with 80% mortality and no approved alternative until recently — MSC therapy offers a genuine, evidence-supported therapeutic option that has earned regulatory recognition on three continents. Patients and families considering this treatment should understand both the strength of the phase 2 data and the limitations of the phase 3 experience. At VELAR, we believe this honest framing is essential to informed decision-making.

References

  1. Zeiser R, Blazar BR. Acute graft-versus-host disease — biologic process, prevention, and therapy. New England Journal of Medicine. 2017;377(22):2167-2179. doi:10.1056/NEJMra1609337 ↩
  2. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation. 2012;18(8):1150-1163. doi:10.1016/j.bbmt.2012.04.005 ↩
  3. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. The Lancet. 2009;373(9674):1550-1561. doi:10.1016/S0140-6736(09)60237-3 ↩
  4. Auletta JJ, Eid SK, Wuttisarnwattana P, et al. Mesenchymal stromal cells preserve the graft-versus-leukemia effect while attenuating GVHD. Blood. 2015;125(16):2545-2553. doi:10.1182/blood-2014-09-599613 ↩
  5. Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1):296-307. doi:10.1182/blood-2011-06-364265 ↩
  6. Galleu A, Riffo-Vasquez Y, Trento C, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Science Translational Medicine. 2017;9(416):eaam7828. doi:10.1126/scitranslmed.aam7828 ↩
  7. Di Ianni M, Del Papa B, De Ioanni M, et al. Mesenchymal cells recruit and regulate T regulatory cells. Experimental Hematology. 2008;36(3):309-318. doi:10.1016/j.exphem.2007.11.007 ↩
  8. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Molecular Therapy. 2012;20(1):14-20. doi:10.1038/mt.2011.211 ↩
  9. Karlsson H, Samarasinghe S, Ball LM, et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood. 2008;112(3):532-541. doi:10.1182/blood-2007-10-119370 ↩
  10. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. The Lancet. 2004;363(9419):1439-1441. doi:10.1016/S0140-6736(04)16104-7 ↩
  11. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. The Lancet. 2008;371(9624):1579-1586. doi:10.1016/S0140-6736(08)60690-X ↩
  12. Kurtzberg J, Prockop S, Teira P, et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biology of Blood and Marrow Transplantation. 2014;20(2):229-235. doi:10.1016/j.bbmt.2013.11.001 ↩
  13. Prasad VK, Lucas KG, Kleiner GI, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stromal cells (remestemcel-L) in pediatric patients with steroid-refractory acute GVHD: phase III results. Biology of Blood and Marrow Transplantation. 2011;17(8):1164-1173. doi:10.1016/j.bbmt.2010.12.230 ↩
  14. Kebriaei P, Hayes J, Daly A, et al. A multicenter, real-world evidence analysis of mesenchymal stromal cell therapy for acute graft-versus-host disease. Transplantation and Cellular Therapy. 2023;29(3):172.e1-172.e10. doi:10.1016/j.jtct.2022.12.009 ↩
  15. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩